These findings highlight cytotoxic CD8+ T cells as potential mediators of axonal loss in the demyelinated CNS (6–8) and suggest that these cells may be promising therapeutic targets to specifically prevent neurodegeneration and secondary brain atrophy in patients with progressive MS (9, 10). Here, CD8A is linked to myeloid sarcoma.